Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Jefferies Financial Group

Analysts at Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a report released on Monday. The brokerage set a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on the company. BTIG Research dropped their price objective on Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. UBS Group upped their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $108.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. JPMorgan Chase & Co. lifted their price target on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, B. Riley Financial boosted their price objective on shares of Kymera Therapeutics from $80.00 to $117.00 and gave the company a “buy” rating in a research report on Monday, December 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and an average target price of $119.50.

Kymera Therapeutics Stock Up 2.3%

Shares of NASDAQ:KYMR traded up $1.81 during midday trading on Monday, hitting $80.84. 120,857 shares of the stock traded hands, compared to its average volume of 772,315. The business’s 50 day moving average is $79.21 and its two-hundred day moving average is $68.50. The stock has a market capitalization of $6.60 billion, a PE ratio of -21.97 and a beta of 2.20. Kymera Therapeutics has a one year low of $19.44 and a one year high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same period in the previous year, the business earned ($0.88) earnings per share. The firm’s revenue for the quarter was down 60.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the company’s stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the sale, the chief executive officer owned 666,195 shares in the company, valued at approximately $60,130,760.70. This represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jeremy G. Chadwick sold 25,758 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $83.30, for a total transaction of $2,145,641.40. Following the transaction, the chief operating officer directly owned 68,052 shares of the company’s stock, valued at $5,668,731.60. This represents a 27.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 196,561 shares of company stock valued at $17,097,428 over the last three months. 16.01% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. PNC Financial Services Group Inc. raised its stake in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock valued at $40,000 after buying an additional 770 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after acquiring an additional 424 shares during the last quarter. Larson Financial Group LLC grew its stake in shares of Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after acquiring an additional 349 shares during the last quarter. Osaic Holdings Inc. increased its holdings in shares of Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after acquiring an additional 815 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.